Global PCR multiplex assays market is growing at a CAGR of 7.2% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below: Access Full Report at https://databridgemarketresearch.com/reports/global-pcr-multiplex-assays-market Global PCR multiplex assays market is a highly concentrated market which includes key players and local players. The market has witnessed increased various strategic developments owing to favourable market scenario. The market has a prominent growth in upcoming years due to growing demand for the PCR multiplex assays, booming across healthcare, technological advancements of global PCR multiplex assays, introduction of novel automated systems. The market has witness developments in terms of merger and acquisitions, partnerships or product launches to enhance the product portfolio to meet the rising demand of innovative monitoring technology in PCR multiplex assays. For instance, In February 2019, F. Hoffmann-La Roche Ltd announced the agreement to acquire Spark Therapeutics, Inc. (U.S.), the company is majorly involved in the developing, delivering and discovering gene therapies for genetic diseases and haemophilia, blindness and lysosomal storage. With the proven expertise of Spark Therapeutics, Inc. (U.S.) in gene therapy which will be the major opportunity to expand their product portfolio for gene therapy of serious diseases. F. Hoffmann-La Roche Ltd dominated the PCR multiplex assays market. The other key players existing in the market includes Hologic Inc., Luminex Corporation, BECTON, DICKINSON AND COMPANY, ABBOTT, Thermo Fisher Scientific Inc, QIAGEN, Agilent Technologies Inc, Meso Scale Diagnostics, LLC, Randox Laboratories Ltd., Bio-Techne, Seegene Inc., Olink, Illumina, Inc, Bio-Rad Laboratories, Inc, Abcam Plc, Quanterix, Sysmex Corporation, Siemens, Diasorin, Quest Diagnostics Incorporated, PerkinElmer Inc, Eurofins Scientific, Agena Bioscience, Inc. F. Hoffmann-La Roche Ltd F. Hoffmann-La Roche Ltd headquartered in Basel, Switzerland was founded in 1896. The company focuses on the development of innovative medicines and diagnostic tests worldwide. The company is providing products in three products categories such as instruments, reagents and consumables, assays. The market focused category lies under Instruments, reagents and consumables, assays. The company has two operating business categories such as pharmaceuticals, diagnostics. The market focused category lies under diagnostics businesses category. The company is continuously engaged in strategic relationship to enhance the product and service of the PCR multiplex assays such as,
- In March 2015, F. Hoffmann-La Roche Ltd announced the launch of cobas 6800/8800 Systems which is fully automated and designed for the application including blood donor screening, viral load monitoring, microbiology testing and women’s health. The systems can be also used for the multiplex assays cobas MPX offered by the company for viral load monitoring. The launch of the PCR systems helps laboratories to quantify HBV DNA in less sample volume which ensuring the most preferred system among laboratories.
It has its global networks through direct sales representatives and distributors in the Europe, North America, Latin America, Asia-pacific, Middle East & Africa. The company has various subsidiaries such as Genentech, Inc. (U.S.), Roche Diagnostics Limited (U.K.), Chugai Pharmaceutical Co. (Japan), Flatiron Health, Inc. (U.S.), Ventana Medical Systems (U.S.), Kapa Biosystems, Inc. (U.S.) among others. Hologic Inc. Hologic Inc is headquartered in Massachusetts, U.S., founded in 1985. The company focus to innovate new technologies for women’s health helps the healthcare professionals all over the world to diagnose and treat their patients with precision, certainty and confidence. Hologic Inc offers various products for better life such as breast and skeletal products, GYN surgical products, diagnostic products and medical aesthetics products. The market focused products category lies under diagnostic products. The company operates through five business segments which include diagnostics, breast health, medical aesthetics, GYN surgical and skeletal health. The market focused category lies under diagnostics category. The company is continuously engaged in strategic relationship to enhance the product and services of the PCR multiplex assays such as
- In September 2018, Hologic, Inc. announced the acquisition of Focal Theraputics at an expense of USD 125 Million. This acquisition helped the company tostrengthening their Breast Surgery Franchise and their consistent involvement in the development ehances the capital deployment goals of company.
The company has wide geographic presence in North America, South America, Europe, Asia-Pacific, and Middle East & Africa. It operates through its subsidiaries such as Cynosure (U.S.), Gen-Probe (U.S.), Cytyc(U.S.), Third Wave Technologies, Inc.(U.S.), Emsor S.A.(Spain) amongst others. Luminex Corporation Luminex Corporation headquartered in Austin, Texas was established in 1995. The company focuses towards the manufacturing and suppling biological testing technologies which have wide application in life science, research, diagnostic and pharmaceutical industries. Luminex Corporation offers various innovative solutions for better life such as clinical, research & applied markets. The market focused category lies under clinical. The company is continuously engaged in strategic relationship to enhance the product and services of the PCR multiplex assays such as
- In July 2016, Luminex Corporation announced that they have received FDA approval and CE-IVD marking for their product ARIES M1 System. The product is designed for lower throughput clinical laboratories. The approval enhances the product portfolio based on customer’s feedback leading to the expansion in the market.
The company has global presence in Europe, Asia-Pacific, North America, Others regions. The company has subsidiaries such as Luminex International, Inc. (Delaware), Luminex B.V. (Netherlands), Luminex 2 B.V. (Netherlands), Labpac Pty Ltd (Austalia), Luminex Hong Kong Limited (HongKong), Luminex Debt Holding, LLC, (Delaware) and others.
